Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-501522-38-00 | Other Identifier | EU CT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Venetoclax | Experimental | Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Venetoclax | Drug | oral; film-coated tablets or tablets for oral suspension |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Adverse Events | An adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section. | From first dose of study drug until 30 days following last dose of study drug (up to approximately 5 years). |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
- None.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Arizona Cancer Center - Tucson /ID# 210548 | Tucson | Arizona | 85724 | United States | ||
| UCLA Santa Monica Hematology Oncology /ID# 210551 |
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Los Angeles |
| California |
| 90095 |
| United States |
| Ingalls Memorial Hosp /ID# 210553 | Harvey | Illinois | 60426 | United States |
| Dana-Farber Cancer Institute /ID# 215360 | Boston | Massachusetts | 02215 | United States |
| University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132 | Ann Arbor | Michigan | 48109 | United States |
| Dartmouth-Hitchcock Medical Center /ID# 210555 | Lebanon | New Hampshire | 03756 | United States |
| Swedish Medical Center - Seattle /ID# 213120 | Seattle | Washington | 98104 | United States |
| Royal Prince Alfred Hospital /ID# 239557 | Camperdown | New South Wales | 2050 | Australia |
| St George Hospital /ID# 225589 | Kogarah | New South Wales | 2217 | Australia |
| Liverpool Hospital /ID# 225591 | Liverpool | New South Wales | 2170 | Australia |
| Peter MacCallum Cancer Ctr /ID# 210559 | Melbourne | Victoria | 3000 | Australia |
| Fiona Stanley Hospital /ID# 239480 | Murdoch | Western Australia | 6150 | Australia |
| Perth Blood Institute Ltd /ID# 225592 | Nedlands | Western Australia | 6009 | Australia |
| Duplicate_Medizinische Universitaet Graz /ID# 223817 | Graz | Styria | 8010 | Austria |
| Cliniques Universitaires UCL Saint-Luc /ID# 224327 | Brussels | Brussels Capital | 1200 | Belgium |
| CHUQ- Hôpital de l'Enfant-Jesus /ID# 224616 | Québec | Quebec | G1J 1Z4 | Canada |
| Rigshospitalet /ID# 224213 | Copenhagen Ø | Capital Region | 2100 | Denmark |
| Aarhus Universitetshospital - Skejby /ID# 224214 | Aarhus | Central Jutland | 8200 | Denmark |
| CHU Grenoble - Hopital Michallon /ID# 240497 | La Tronche | Isere | 38700 | France |
| HCL - Hopital Lyon Sud /ID# 213508 | Pierre-Bénite | Rhone | 69495 | France |
| General Hospital of Athens Laiko /ID# 224087 | Athens | Attica | 11527 | Greece |
| General Hospital of Thessaloniki George Papanikolaou /ID# 224088 | Thessaloniki | 57010 | Greece |
| Queen Mary Hospital /ID# 224944 | Hong Kong | 999077 | Hong Kong |
| Beaumont Hospital /ID# 225165 | Dublin | D09 XR63 | Ireland |
| Kobe City Medical Center General Hospital /ID# 241518 | Kobe | Hyōgo | 650-0047 | Japan |
| Duplicate_National Hospital Organization Mito Medical Center /ID# 241986 | Higashi Ibaraki-gun | Ibaraki | 311-3193 | Japan |
| Duplicate_Okayama Medical Center /ID# 241517 | Okayama | Okayama-ken | 701-1192 | Japan |
| National Cancer Center Hospital /ID# 241516 | Chuo-ku | Tokyo | 104-0045 | Japan |
| Centro de Investigacion Clínica Chapultepec SA de CV /ID# 227018 | Morelia | Michoacán | 58260 | Mexico |
| Hospital Universitario Dr. Jose Eleuterio Gonzalez /ID# 227017 | Monterrey | Nuevo León | 64460 | Mexico |
| Aotearoa Clinical Trials /ID# 225596 | Papatoetoe | Auckland | 2025 | New Zealand |
| North Shore Hospital /ID# 225597 | Takapuna | Auckland | 0622 | New Zealand |
| Wellington Regional Hospital /ID# 225593 | Newtown | Wellington Region | 6021 | New Zealand |
| Duplicate_Pratia MCM Krakow /ID# 218561 | Krakow | Lesser Poland Voivodeship | 30-727 | Poland |
| Instytut Hematologii i Transfuzjologii /ID# 225478 | Warsaw | Masovian Voivodeship | 02-776 | Poland |
| SP ZOZ Zespol Szpitali Miejskich w Chorzowie /ID# 225474 | Chorzów | Silesian Voivodeship | 41-500 | Poland |
| IPO Lisboa FG, EPE /ID# 225072 | Lisbon | 1099-023 | Portugal |
| Federal State Budgetary Scientific Institution N.N. Blokhin /ID# 225194 | Moscow | Moscow | 115478 | Russia |
| Regional Oncological Dispensary /ID# 225195 | Penza | Penza Oblast | 440071 | Russia |
| Samsung Medical Center /ID# 240882 | Seoul | Seoul Teugbyeolsi | 06351 | South Korea |
| Hospital Universitario Fundacion Jimenez Diaz /ID# 225476 | Madrid | 28040 | Spain |
| Duplicate_Skane University Hospital Lund /ID# 224747 | Lund | Skåne County | 221 41 | Sweden |
| National Taiwan University Hospital /ID# 224946 | Taipei City | Taipei | 100 | Taiwan |
| China Medical University Hospital /ID# 224945 | Taichung | 40447 | Taiwan |
| Ankara Univ Medical Faculty /ID# 225043 | Ankara | 06590 | Turkey (Türkiye) |
| Istanbul University Istanbul Medical Faculty /ID# 225045 | Istanbul | 34093 | Turkey (Türkiye) |
| Vehbi Koc vakfi Amerikan Hasta /ID# 225046 | Istanbul | 34365 | Turkey (Türkiye) |
| Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council /ID# 240575 | Dnipro | 49102 | Ukraine |
| Derriford Hospital and the Royal Eye Infirmary /ID# 218731 | Plymouth | Devon | PL6 8DH | United Kingdom |
| Leicester Royal Infirmary /ID# 240468 | Leicester | England | LE1 5WW | United Kingdom |
| University College London Hospital /ID# 240467 | London | Greater London | NW1 2BU | United Kingdom |
| Kings College Hospital NHS Foundation Trust /ID# 218735 | London | Greater London | SE5 9RS | United Kingdom |
| University Hospital Southampton NHS Foundation Trust /ID# 225161 | Southampton | Hampshire | SO16 6YD | United Kingdom |
| Blackpool Teaching Hospitals NHS Foundation Trust /ID# 225163 | Blackpool | FY3 8NR | United Kingdom |
| Clatterbridge Cancer Centre - Liverpool /ID# 218736 | Liverpool | L7 8YA | United Kingdom |
| The Royal Wolverhampton NHS Trust /ID# 225164 | Wolverhampton | WV10 0QP | United Kingdom |
| ID | Term |
|---|---|
| D015451 | Leukemia, Lymphocytic, Chronic, B-Cell |
| D015470 | Leukemia, Myeloid, Acute |
| D009101 | Multiple Myeloma |
| D008228 | Lymphoma, Non-Hodgkin |
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D015448 | Leukemia, B-Cell |
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007951 | Leukemia, Myeloid |
| D054219 | Neoplasms, Plasma Cell |
| D020141 | Hemostatic Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006474 | Hemorrhagic Disorders |
| D008223 | Lymphoma |
Not provided
Not provided
| ID | Term |
|---|---|
| C579720 | venetoclax |
Not provided
Not provided
Not provided